The New England Journal of Medicine.

Experimental monoclonal antibody not efficacious in Phase 3 trial

Preliminary results of a Phase 3, randomized, placebo-controlled clinical trial testing the investigative monoclonal antibody LY-CoV555 in hospitalized COVID-19 patients were published today in The New England Journal of Medicine.